Topotecan for Irinotecan-Refractory SCLC
Salvage Treatment With Topotecan in Patients With Irinotecan-Refractory Small Cell Lung Cancer
Although the efficacy of topotecan as second-line chemotherapy for SCLC has been consistently demonstrated in phase II/III clinical trials, the choice of irinotecan as first-line therapy prevented use of the evidence-based option.
This pilot study will be conducted to determine the activity and safety of topotecan in SCLC patients refractory to first-line therapy with irinotecan and platinum.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current commonly used second-line approaches for SCLC include re-induction with first-line therapy for chemosensitive disease, or single-agent topotecan. Although the efficacy of topotecan as second-line chemotherapy for SCLC has been consistently demonstrated in a number of clinical studies, the choice of irinotecan as first-line therapy prevented use of the evidence-based option such as topotecan. Topotecan and irinotecan are cytotoxic agents that inhibit same intracellular pathway, namely topoisomerase I, which is an enzyme involved in DNA replication and RNA transcription.
Although their mechanism of action is similar, the preclinical and clinical data of these two drugs have some notable differences. Topotecan and irinotecan have different spectra of antitumor activity in various models of human cancer. Clinical data support that these agents may have different spectra of activity. The differences in antitumor activities may also reflect different mechanisms of resistance. Furthermore, topotecan and irinotecan have different limiting toxicities (myelosuppression and diarrhea, respectively).
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Incheon, Korea, Republic of, 405 760
- Gachon University Gil Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically or cytologically proven SCLC
- refractory to prior irinotecan-based chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- age between 18 and 75 years
- no active brain or leptomeningeal metastases
- adequate hematologic, hepatic and renal functions
- at least one measurable lesion(s)
Exclusion Criteria:
- pregnant or lactating women
- patients with active infection
- extensive radiotherapy within the previous 4 weeks
- previous other malignancies with the exception of adequately treated non-melanoma skin cancer or in situ cervical cancer
- any severe comorbid illness
- a known history of anaphylaxis of any origin
- history of severe adverse events to the drug used in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Response rate
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Safety
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eun Kyung Cho, MD, Gachon University Gil Medical Center, Incheon, Korea
Study record dates
Study Major Dates
Study Start
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GMO-LU-51
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.